期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 198, 期 4, 页码 641-653出版社
WILEY
DOI: 10.1111/bjh.18226
关键词
amyloidosis; mass spectrometry; MGUS; MRD; multiple myeloma
类别
Mass spectrometry techniques offer a highly sensitive method for evaluating and monitoring paraproteins compared to standard electrophoretic techniques, providing valuable insights for clinical assessment and clinical trial enrollment. The increased sensitivity of these assays helps detect and monitor monoclonal proteins more effectively and can increase detection rates of low-level monoclonal proteins.
Mass spectrometry (MS) techniques provide a highly sensitive methodology for the assessment and monitoring of paraproteins compared to standard electrophoretic techniques. The International Myeloma Working Group (IMWG) recently approved the use of intact light chain matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) in lieu of immunofixation in the clinical assessment of patients and the assessment of patients enrolled on clinical trials. The increased sensitivity of these assays may help to detect and monitor monoclonal proteins (MP) in many patients with previously non-measurable disease, will reduce complete response (CR) rates and increase detection of low-level MP. The ability to track the unique mass or amino acid sequence of the MP also eliminates interference from therapeutic monoclonal antibodies (tmAbs) in most patients with IgG kappa myeloma. The intact light chain assays also provide structural information about the monoclonal light chain, including the presence of N-linked glycosylation, which has been shown to be commoner on amyloidogenic light chains and may have prognostic significance in monoclonal gammopathy of undetermined significance (MGUS). In this review, we discuss these issues alongside differences in the analytical and practical aspects related to the different MS assays under development and the challenges for MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据